Highlights

  • FY26 operating revenue reached US$15,797 million across three reported business segments.
  • CSL Behring reported US$11,387 million in revenue, including plasma-derived therapies.
  • FY26 underlying NPATA attributable to shareholders was approximately US$3.1 billion.
  • The group recorded a statutory loss after substantial impairment and restructuring charges.
  • Plasma manufacturing efficiency, haemophilia treatments and product access remain operational priorities.

CSL Limited (ASX:CSL) develops, manufactures and supplies medicines for serious and rare diseases, alongside influenza vaccines, through CSL Behring, CSL Vifor and CSL Seqirus. Its operations cover plasma-derived therapies, recombinant and gene-based treatments, nephrology products and vaccine manufacturing. FY26 results placed renewed emphasis on plasma collection productivity, manufacturing efficiency and the financial effects of restructuring and impairment charges.

What FY26 Results Showed

For the year ended 30 June 2026, CSL Limited (ASX:CSL) reported total operating revenue of US$15,797 million, compared with US$15,558 million in FY25. CSL Behring contributed US$11,387 million, CSL Vifor US$2,379 million and CSL Seqirus US$2,031 million. The differing segment trends underline the variety of medicines and end markets within the group.

Underlying net profit after tax and amortisation (NPATA) attributable to CSL shareholders was approximately US$3.1 billion, down 2% on a constant-currency basis. Operating cash flow was US$3,512 million. A reported statutory net loss of about US$2.6 billion reflected major restructuring and impairment-related charges; it should not be confused with underlying earnings.

Plasma Fractionation and Manufacturing Capacity

Plasma fractionation separates collected human plasma into therapeutic proteins, including immunoglobulins and albumin. These medicines serve patients with immune disorders and other serious conditions. CSL Limited (ASX:CSL) identifies plasma yield and collection efficiency as important operational levers because processing efficiency influences the quantity of medicines obtainable from donated plasma.

CSL reported plans for approximately US$1.5 billion of investment in its US manufacturing footprint over five years, including expansion at Kankakee, Illinois. These are investment plans, not completed production increases. In FY26, CSL Behring recorded immunoglobulin revenue of US$6,248 million. This product category forms a substantial component of the group’s plasma business.

Recombinant Treatments and Haemophilia Care

Alongside plasma-derived products, CSL Limited (ASX:CSL) markets recombinant therapies manufactured using biological engineering rather than extraction from donated plasma. Its published product portfolio includes AFSTYLA, a recombinant factor VIII treatment for haemophilia A, and HEMGENIX, a gene therapy for eligible adults with haemophilia B. The technologies differ in their administration and treatment approaches.

CSL disclosed a July 2026 update stating that limited HEMGENIX supply had resumed in April and that 22 people had received treatment through commercial and clinical-trial settings since that resumption. Product availability, manufacturing controls and regulatory requirements therefore remain relevant to the commercial delivery of these specialised therapies.

Segment Pressures and Capital Allocation

CSL Limited (ASX:CSL) reported US$2,031 million in FY26 revenue for CSL Seqirus and US$2,379 million for CSL Vifor. The annual report identifies challenges from influenza-market conditions and competition in some iron products. It also records the withdrawal of TAVNEOS in European markets, adding a product-specific regulatory issue.

The group maintained FY26 total dividends of US$2.92 per share and completed an approximately A$1 billion share buy-back programme. These shareholder distributions occurred alongside continuing requirements for research, manufacturing investment and working capital. The FY26 results also disclosed US$176 million of cost savings realised under transformation initiatives.

Key Insights

CSL Limited (ASX:CSL) combines plasma collection and fractionation with recombinant, gene-based and vaccine platforms. FY26 reporting shows recurring demand in parts of its medicine portfolio alongside different trading conditions across its divisions. The distinction between underlying profitability and statutory impairment charges is central to interpreting the year. Manufacturing efficiency, product supply, compliance and the allocation of investment across business segments remain the principal operational themes.